Pfizer Extends Real-World Data AI Drug Development Deal with CytoReason in $110 Million 5-Year Deal

September 21, 2022

Pfizer has signed a deal to extend its partnership with CytoReason for another 5 years. The deal, which totalled $110 million, will support CytoReason’s artificial intelligence (AI) platform that Pfizer has leveraged to accelerate the pharma giant’s drug development projects. CytoReason will receive $20 million up front, with the remainder spread across the duration of the deal.

According to Andrea Park, “CytoReason’s platform takes in real-world data from pharmaceutical partners then uses that information to construct tissue- and cell-specific models that simulate individual diseases. The company’s machine learning AI can then be used to explore those models and highlight differences between various patient groups and treatments, potentially identifying more effective routes of attack for new drug candidates.”

To read more, click here.

(Source: Fierce Biotech, September 20th, 2022)

Share This Story!